Suppr超能文献

纤溶酶原激活物抑制剂-1 与结直肠肿瘤的相关性。

Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.

机构信息

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Gut Liver. 2013 Sep;7(5):519-23. doi: 10.5009/gnl.2013.7.5.519. Epub 2013 Jun 11.

Abstract

BACKGROUND/AIMS: Plasminogen activator inhibitor-1 (PAI-1) is important for tumor growth, Invasion, and metastasis. In this study, we investigated the relationship between plasma levels of PAI-1 and colorectal adenomas.

METHODS

We reviewed the medical records of 3,136 subjects who underwent colonoscopy as a screening exam. The subjects were classified into a case group with adenomas (n=990) and a control group (n=2,146). Plasma PAI-1 levels were categorized into three groups based on tertile.

RESULTS

The plasma levels of PAI-1 were significantly higher in adenoma cases than in controls (p=0.023). The prevalence of colorectal adenomas increased significantly with increasing levels of PAI-1 (p=0.038). In the adenoma group, advanced pathologic features, size, and number of adenomas did not differ among the three groups based on tertiles for plasma PAI-1 levels. Using multivariate analysis, we found that plasma level of PAI-1 was not associated with the risk of colorectal adenomas (p=0.675). Adjusted odds ratios for colorectal adenomas according to increasing plasma levels of PAI-1 were 0.980 (95% confidence interval [CI], 0.768 to 1.251) for the second-highest plasma level and 1.091 (95% CI, 0.898 to 1.326) for the highest level, compared with the lowest levels.

CONCLUSIONS

These results suggest that elevated plasma PAI-1 levels are not associated with the risk of colorectal neoplasms.

摘要

背景/目的:纤溶酶原激活物抑制剂-1(PAI-1)对肿瘤的生长、侵袭和转移很重要。本研究旨在探讨血浆 PAI-1 水平与结直肠腺瘤之间的关系。

方法

我们回顾性分析了 3136 例接受结肠镜筛查的患者的病历资料。根据有无腺瘤将患者分为病例组(n=990)和对照组(n=2146)。根据三分类法将血浆 PAI-1 水平分为三组。

结果

病例组患者的血浆 PAI-1 水平明显高于对照组(p=0.023)。随着 PAI-1 水平的升高,结直肠腺瘤的患病率显著增加(p=0.038)。在腺瘤组中,根据血浆 PAI-1 水平三分位,高级别病理特征、腺瘤大小和数量在三组之间无显著差异。多变量分析显示,血浆 PAI-1 水平与结直肠腺瘤风险无关(p=0.675)。根据血浆 PAI-1 水平升高,结直肠腺瘤的调整比值比分别为第二高血浆水平时的 0.980(95%置信区间,0.768 至 1.251)和最高水平时的 1.091(95%置信区间,0.898 至 1.326),与最低水平相比。

结论

这些结果表明,血浆 PAI-1 水平升高与结直肠肿瘤的风险无关。

相似文献

引用本文的文献

6
Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma.Bmi-1和PAI-1在食管鳞状细胞癌中的表达。
World J Gastroenterol. 2014 May 14;20(18):5533-9. doi: 10.3748/wjg.v20.i18.5533.

本文引用的文献

3
The plasminogen activator system and cancer.纤溶酶原激活物系统与癌症。
Pathophysiol Haemost Thromb. 2008;36(3-4):184-94. doi: 10.1159/000175156. Epub 2009 Jan 27.
4
The plasminogen activator inhibitor "paradox" in cancer.癌症中的纤溶酶原激活物抑制剂“悖论”
Immunol Lett. 2008 Jun 30;118(2):116-24. doi: 10.1016/j.imlet.2008.03.017. Epub 2008 May 2.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验